BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
RDEA119 and Sorafenib Combination Dose Escalation Study
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 62
- Registration Number
- NCT00785226
- Locations
- 🇺🇸
UPenn, Philadelphia, Pennsylvania, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center, Los Angeles, California, United States
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A
Completed
- Conditions
- Hematologic DiseaseBlood Coagulation Disorders
- Interventions
- Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 38
- Registration Number
- NCT00782470
Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste
Phase 3
Completed
- Conditions
- Onychomycosis
- Interventions
- Drug: Placebo creamDrug: Bifonazole cream 1%
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 693
- Registration Number
- NCT00781820
Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.
Phase 4
Completed
- Conditions
- Energy Expenditure
- Interventions
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 22
- Registration Number
- NCT00781586
Rehabilitation Study in MS Patients
Phase 4
Terminated
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Interferon beta-1b, FRP within 15 days after randomizationDrug: Interferon beta-1b, FRP about 6 weeks after randomization
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4
- Registration Number
- NCT00780455
BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status
Phase 2
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Rivaroxaban (BAY59-7939)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 36
- Registration Number
- NCT00779064
Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
Phase 3
Completed
- Conditions
- Oral ContraceptiveHeadachePelvic Pain
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027)Drug: Encapsulated Microgynon + Placebo
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 449
- Registration Number
- NCT00778609
A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®
Completed
- Conditions
- Carcinoma, Renal CellCarcinoma, Renal Cell (Advanced)
- Interventions
- Drug: Sorafenib (Nexavar, BAY43-9006)
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2012-06-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 71
- Registration Number
- NCT00771147
Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)
Phase 4
Completed
- Conditions
- Constipation
- Interventions
- Other: Placebo, maltodextrin 500 powder for solutionDrug: Polyethylene glycol 3350
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 203
- Registration Number
- NCT00770432
BAY 77-1931 Long-term Extension From Phase II Study
Phase 2
Completed
- Conditions
- Hyperphosphatemia
- Interventions
- Drug: BAY 77-1931
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 145
- Registration Number
- NCT00769496
© Copyright 2025. All Rights Reserved by MedPath